New hope for tough myeloma: Two-Drug combo takes on relapsed cancer
NCT ID NCT06948084
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial compares a new combination of daratumumab and teclistamab against standard treatments for high-risk multiple myeloma that has relapsed or not responded to therapy. About 80 adults will be randomly assigned to either the new combo or usual care. The goal is to see if the new approach can reduce cancer cells to undetectable levels more effectively.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- daratumumab and teclistamab
- What this could lead to
- If this works, it could offer a more effective treatment option for high-risk multiple myeloma patients whose cancer has returned or not responded to prior therapy.
- What could go wrong
- This is a small, early phase II trial with only 80 participants, so results may not apply broadly. The new combination may cause side effects or fail to outperform existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered donor cells could outsmart relapsed myeloma
- Can a Triple-Drug cocktail tame resistant myeloma?
- Can a One-Two drug punch beat back Hard-to-Treat myeloma?
- CAR-T breakthroughs come with infection risks – new study aims to decode them
- Double-barreled CAR t therapy takes aim at hard-to-treat myeloma
- Can a drug stop dangerous side effects of new myeloma therapies?